IBB: iShares Biotechnology ETF
About
IBB was created on 2001-02-05 by iShares. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 7167.86m in AUM and 211 holdings. IBB tracks the performance of a modified market-cap-weighted index of US biotechnology companies listed on US exchanges.
Current Value
$133.551 Year Return
Current Value
$133.551 Year Return
Key Details
Assets Under Management
$6.66B
Div Yield %
0.34%
P/E Ratio
24.34
Net Asset Value
$133.04
Expense Ratio
0.45%
1Y ETF Return
0.13%
Strategies that include IBB
Stock's related to IBB
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| TECH | 65.59% | $10.55B | +4.49% | 0.48% |
| PGEN | 65.56% | $228.91M | -28.00% | 0.00% |
| NTLA | 64.46% | $1.44B | -50.35% | 0.00% |
| TMO | 63.38% | $194.74B | +5.54% | 0.30% |
| CRL | 63.05% | $9.52B | -3.20% | 0.00% |
| BEAM | 62.39% | $2.09B | -9.52% | 0.00% |
| RCKT | 62.35% | $1.20B | -39.83% | 0.00% |
| DNLI | 61.50% | $3.50B | +33.66% | 0.00% |
| RVTY | 61.48% | $13.38B | +23.61% | 0.26% |
| AMGN | 61.04% | $150.48B | +6.52% | 3.20% |
| CRSP | 60.82% | $4.01B | -30.49% | 0.00% |
| IQV | 59.59% | $34.73B | -7.77% | 0.00% |
| VIR | 59.23% | $954.40M | -26.51% | 0.00% |
| PLRX | 58.69% | $778.32M | -9.55% | 0.00% |
| ALEC | 58.45% | $377.04M | -19.46% | 0.00% |
| IDYA | 58.26% | $2.24B | -15.21% | 0.00% |
| CLFD | 57.99% | $398.66M | +4.48% | 0.00% |
| RXRX | 57.98% | $1.80B | -4.13% | 0.00% |
| ILMN | 57.14% | $21.41B | +44.38% | 0.00% |
| BIIB | 57.10% | $22.65B | -32.30% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CHD | 0.34% | $27.18B | +19.50% | 1.03% |
| LMT | -0.45% | $126.40B | +18.99% | 2.36% |
| SCKT | 0.51% | $10.88M | +15.32% | 0.00% |
| STG | -0.58% | $35.67M | +7.92% | 0.00% |
| QTTB | 0.92% | $354.34M | +188.64% | 0.00% |
| FATBB | 0.97% | $81.94M | -12.91% | 11.69% |
| RNR | 1.23% | $13.74B | +23.09% | 0.58% |
| NEUE | 1.28% | $40.93M | -34.13% | 0.00% |
| LITB | -1.44% | $35.48M | -75.45% | 0.00% |
| BTCT | -1.45% | $42.61M | +353.33% | 0.00% |
| COR | -1.46% | $47.48B | +21.20% | 0.86% |
| GAN | -1.56% | $83.39M | +21.19% | 0.00% |
| CMG | 1.69% | $80.02B | +33.62% | 0.00% |
| CME | -1.97% | $82.76B | +9.21% | 1.98% |
| BACK | 2.01% | $1.76M | -32.90% | 0.00% |
| OXBR | -2.09% | $19.05M | +178.18% | 0.00% |
| UUU | 2.17% | $4.97M | -41.89% | 0.00% |
| PRPO | -2.22% | $9.10M | -13.65% | 0.00% |
| CCEC | 2.32% | $1.02B | +28.03% | 3.26% |
| NOC | 2.43% | $71.54B | +4.23% | 1.60% |
ETF's related to IBB
News
SeekingAlpha
While the drop has resulted in extreme underperformance versus the S&P 500, it has also resulted in the sector's weight in the S&P 500 falling dramatically.
SeekingAlpha
SPDR® S&P Biotech ETF had its worst week since 2020, but the sector remains undervalued. Read why XBI is a strong buy for patient investors.
SeekingAlpha
Many investors are now assessing how a new administration will impact the economy and markets. TD Asset Management's Justin Flowerday discusses the possible market drivers going forward.
SeekingAlpha
The Act curbs US-China biotech collaborations, spurring opportunities for emerging markets in pharma supply chains.
SeekingAlpha
Healthcare companies often grab headlines for their drug innovations. But itâs notoriously difficult to handicap outcomes, and we think investors' focus should be on business fundamentals.
SeekingAlpha
By Shannon L. Saccocia, CFAThe rush into risk assets could last through the end of the year, but thereafter the outlook becomes more complicated.After...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.